Hanmi Pharm licenses its obesity drug candidate HM17321 to Genentech, James LaValle weighs in after FDA advisors back most ...
Mechanistically, HM17321 is a Ucn2 analog enabling a non-GLP-1 approach aimed at improving body composition by selectively reducing adiposity while preserving muscle mass and function. Preclinical ...
Daniel Dornbusch (ddornbusch@mba2003.hbs.edu) leads the medical education team in Genentech?s Hematology Division. He previously worked for Genzyme, specializing in business, product, and corporate ...
Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy ...
Ying Huang, Ph.D., is the Chief Executive Officer and Board Director of K2 Therapeutics, and Strategic Advisor, APAC at MPM BioImpact. He brings over 9 years of experience in research and development ...
Amplitude Therapeutics and Chai Discovery ink AI and RNA collaborations with Eli Lilly and Bristol Myers Squibb, Norstella's ...
Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...
From an approval for a disease affecting 900 people worldwide to a new drug class in multiple myeloma and a $322 million ...
President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for ...
K2 Therapeutics CEO Ying Huang discusses why government investment and US-trained returnees have made China's biotech ...
However, in a conversation with Norstella’s VP of thought leadership Dan Chancellor, he explained that pipeline creation has ...
Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results